AEQUUS PHARMACEUTICALS INCAEQUUS PHARMACEUTICALS INCAEQUUS PHARMACEUTICALS INC

AEQUUS PHARMACEUTICALS INC

No trades
See on Supercharts
Market capitalization
‪1.72 M‬CAD
−0.025CAD
‪−3.21 M‬CAD
‪1.38 M‬CAD
‪112.80 M‬
Beta (1Y)
0.51

About AEQUUS PHARMACEUTICALS INC

CEO
Douglas Glen Janzen
Headquarters
Vancouver
Employees (FY)
15
Founded
2013
ISIN
CA0076361033
FIGI
BBG0089LFZ20
Aequus Pharmaceuticals, Inc. engages in the development and commercialization of alternatives to currently approved drugs. Its products include, Tacrolimus IR, are used for the treatment of refractory rejection in patients receiving allogenic liver, kidney or heart transplants; and Vistitan, and are used for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. The company was founded by Fotios Plakogiannis, Charlie Perperidis, Peter Gregory Wilson, and Alexander Goumeniouk on January 3, 2013 and is headquartered in Vancouver, Canada.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of AQS is 0.015 CAD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TSXV exchange AEQUUS PHARMACEUTICALS INC stocks are traded under the ticker AQS.
AEQUUS PHARMACEUTICALS INC is going to release the next earnings report on May 1, 2024. Keep track of upcoming events with our Earnings Calendar.
AQS stock is 0% volatile and has beta coefficient of 0.51. Check out the list of the most volatile stocks — is AEQUUS PHARMACEUTICALS INC there?
Yes, you can track AEQUUS PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
AQS stock hasn't changed in a week, the month change is a 25.00% fall, over the last year AEQUUS PHARMACEUTICALS INC has showed a 50.00% decrease.
AQS net income for the last quarter is ‪−803.65 K‬ CAD, while the quarter before that showed ‪−700.88 K‬ CAD of net income which accounts for −14.66% change. Track more AEQUUS PHARMACEUTICALS INC financial stats to get the full picture.
Today AEQUUS PHARMACEUTICALS INC has the market capitalization of ‪1.72 M‬, it has decreased by 10.00% over the last week.
No, AQS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AQS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AEQUUS PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
AQS reached its all-time high on Mar 17, 2015 with the price of 0.800 CAD, and its all-time low was 0.010 CAD and was reached on Feb 29, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 19, 2024, the company has 15.00 employees. See our rating of the largest employees — is AEQUUS PHARMACEUTICALS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AEQUUS PHARMACEUTICALS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AEQUUS PHARMACEUTICALS INC stock shows the sell signal. See more of AEQUUS PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AEQUUS PHARMACEUTICALS INC EBITDA is ‪−2.44 M‬ CAD, and current EBITDA margin is −171.64%. See more stats in AEQUUS PHARMACEUTICALS INC financial statements.